Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Piazza, Rocco Giovanni"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bossi, Elisa, Aroldi, Andrea, Borin, Lorenza Maria, Verga, Luisa, Fontana, Diletta, Cocito, Federica, Manghisi, Beatrice, Rindone, Giovanni, Cavalca, Fabrizio, Ripamonti, Alessia, Raggi, Monica, Malandrin, Sergio Maria Ivano, Cavallero, Annalisa, Antolini, Laura, Bonardi, Diego, Piazza, Rocco Giovanni, Gambacorti‐Passerini, Carlo
Publikováno v:
EJHaem; Nov2022, Vol. 3 Issue 4, p1201-1208, 8p
Autor:
Massimino, Luca, Palmieri, Orazio, Facoetti, Amanda, Fuggetta, Davide, Spanò, Salvatore, Lamparelli, Luigi Antonio, D'Alessio, Silvia, Cagliani, Stefania, Furfaro, Federica, D'Amico, Ferdinando, Zilli, Alessandra, Fiorino, Gionata, Parigi, Tommaso Lorenzo, Noviello, Daniele, Latiano, Anna, Bossa, Fabrizio, Latiano, Tiziana, Pirola, Alessandra, Mologni, Luca, Piazza, Rocco Giovanni, Abbati, Danilo, Perri, Francesco, Bonini, Chiara, Peyrin-Biroulet, Laurent, Malesci, Alberto, Jairath, Vipul, Danese, Silvio, Ungaro, Federica
Publikováno v:
Gut; 2023, Vol. 72 Issue: 10 p1838-1847, 10p
Autor:
Azzoni, Emanuele, Barone, Cristiana, Orsenigo, Roberto, Cazzola, Anna, Patelli, Arianna, Nicholls, Matthew, Mauri, Mario, Meneveri, Raffaella, Fantin, Alessandro, Brunelli, Silvia, Piazza, Rocco Giovanni
Publikováno v:
In Experimental Hematology 2022 111 Supplement:S58-S59
Publikováno v:
American journal of hematology. 91(1)
The efficacy of second-line treatment for chronic myeloid leukemia (CML) plays an important role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase inhibitors (TKIs) are presently available: bosutinib, dasatinib, nilotin
Autor:
PIAZZA, ROCCO GIOVANNI, PIROLA, ALESSANDRA, FONTANA, DILETTA, MAGISTRONI, VERA, BORIN, LORENZA MARIA, GAMBACORTI PASSERINI, CARLO, Cecchetti, C, Donandoni, C, Mezzatesta, C, Bianchi, B, Fumagalli, M
Publikováno v:
American journal of hematology. 90(12)
Incorrect Drug Name: In the Viewpoint titled "Imatinib - A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015" published online March 12, 2015, in JAMA Oncology (doi:10.1001/jamaoncol.2015.50), an incorrect dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1299::547aadff0daff6f5ee40d52b356ca225
http://hdl.handle.net/10281/95129
http://hdl.handle.net/10281/95129
Publikováno v:
American journal of hematology. 90(2)
The initial treatment for chronic myeloid leukemia in chronic phase (CP-CML) represents a complex process, which includes a prompt and precise diagnosis, the choice among three available tyrosine kinase inhibitors (TKIs), and the initial management o
Autor:
VIGANO', ILARIA, ANTOLINI, LAURA, PIAZZA, ROCCO GIOVANNI, GAMBACORTI PASSERINI, CARLO, Di Giacomo, N, Bozzani, S
Publikováno v:
American journal of hematology. 89(10)
Imatinib mesylate radically changed the natural history of chronic myeloid leukemia (CML). The recent availability of alternative tyrosine kinase inhibitors (TKIs) renders the clinical management of CML more complex. In this article, we summarize our
Autor:
REDAELLI, SARA, PERINI, PIETRO, CECCON, MONICA, PIAZZA, ROCCO GIOVANNI, RIGOLIO, ROBERTA, GAMBACORTI PASSERINI, CARLO, Boschelli, F, Giannoudis, A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1299::c03a756594be6a05f3994f95c0402bba
http://hdl.handle.net/10281/59614
http://hdl.handle.net/10281/59614